Kimelman & Baird, LLC Regeneron Pharmaceuticals, Inc. Call Options Transaction History
Kimelman & Baird, LLC
- $1.21 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding REGN
# of Institutions
1,512Shares Held
84.5MCall Options Held
926KPut Options Held
1.22M-
Vanguard Group Inc Valley Forge, PA9.32MShares$7.5 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$6.79 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.49MShares$6.02 Billion0.65% of portfolio
-
State Street Corp Boston, MA4.84MShares$3.89 Billion0.23% of portfolio
-
Capital World Investors Los Angeles, CA4.3MShares$3.46 Billion0.72% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $86.2B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...